Oaktree Acquisition Corp. III Life Sciences’ (NASDAQ:OACCU – Get Free Report) lock-up period will expire on Tuesday, April 22nd. Oaktree Acquisition Corp. III Life Sciences had issued 17,500,000 shares in its public offering on October 24th. The total size of the offering was $175,000,000 based on an initial share price of $10.00. After the expiration of Oaktree Acquisition Corp. III Life Sciences’ lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.
Oaktree Acquisition Corp. III Life Sciences Stock Performance
NASDAQ OACCU opened at $10.31 on Monday. Oaktree Acquisition Corp. III Life Sciences has a fifty-two week low of $9.99 and a fifty-two week high of $10.60. The business’s fifty day moving average is $10.26.
Institutional Trading of Oaktree Acquisition Corp. III Life Sciences
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Rangeley Capital LLC acquired a new stake in Oaktree Acquisition Corp. III Life Sciences during the 4th quarter worth approximately $101,000. Athos Capital Ltd acquired a new stake in Oaktree Acquisition Corp. III Life Sciences in the fourth quarter valued at $507,000. Kepos Capital LP bought a new position in Oaktree Acquisition Corp. III Life Sciences during the 4th quarter worth $709,000. Whitebox Advisors LLC acquired a new position in Oaktree Acquisition Corp. III Life Sciences during the 4th quarter worth about $2,532,000. Finally, Affinity Asset Advisors LLC acquired a new stake in shares of Oaktree Acquisition Corp. III Life Sciences in the fourth quarter valued at about $2,538,000.
About Oaktree Acquisition Corp. III Life Sciences
We are a newly organized blank check company incorporated on June 28, 2024, as a Cayman Islands exempted company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination.
Recommended Stories
- Five stocks we like better than Oaktree Acquisition Corp. III Life Sciences
- Basic Materials Stocks Investing
- With a 60%+ Upside, There’s Plenty to Love About Lovesac
- Trading Halts Explained
- J.B. Hunt Transport Overcorrects Into a Buying Opportunity
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- AppLovin: Can Record Profits Overcome Market Skepticism?
Receive News & Ratings for Oaktree Acquisition Corp. III Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oaktree Acquisition Corp. III Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.